New data reveals insured patients can still face significant out- of-pocket dental costs

[vc_row][vc_column][vc_column_text]AIHW spokesperson Dr Adrian Webster said that good oral health is fundamental to general health and wellbeing. Without it, a person’s general quality of life and the ability to eat, speak and socialise is compromised, resulting in pain, discomfort and embarrassment.

‘However, for many Australians, cost may be a barrier to ensuring they receive the care they need, when they need it,’ he said.

The report, Oral health and dental care in Australia, draws together data from a variety of sources to explore the oral health of Australians and their use of dental care services.

Recent data published by the Australian Bureau of Statistics shows that in 2017–18, half (50%) of Australians aged 15 and over said they had seen a dentist over the past 12 months. However, a national study of adult oral health conducted by the University of Adelaide found that in the same year, about 2 in 5 (39%) said they avoided or delayed visiting a dentist due to the cost, and this was more common among people who were not covered by private health insurance.

‘More than half (52%) of people without insurance said they avoided the dentist because of the cost, compared with about 1 in 4 (26%) people with insurance,’ Dr Webster said.

Even those people who receive dental treatment using their private health insurance can face substantial out-of-pocket costs. For example, the median out-of-pocket cost after using their health insurance for a full crown was $786. However, there was a great deal of variation between patients, with some paying as little as $26 out of their own pockets, and others paying $1,989.

Other, more routine procedures also saw great variation in out-of-pocket costs even after private health insurance payments.

‘The median out-of-pocket cost for people using private health insurance for a preventive service to remove plaque or stains was $16, but some patients paid up to $82, while others paid nothing,’ Dr Webster said.

Today’s report also suggests that some Australians are more likely to see cost as a barrier than other groups. For example, Aboriginal and Torres Strait Islander people were more likely to report avoiding the dentist due to cost than non-Indigenous Australians (49% compared with 39%), and females were more likely than males (43% compared with 35%).

‘Visiting a dentist regularly has many benefits. These visits provide an opportunity for preventive dental care, which can stop problems developing, and can facilitate treatment to repair or reverse damage to teeth and gums,’ Dr Webster said.[/vc_column_text][/vc_column][/vc_row]

International collaboration on digital health best practice supports global response to COVID-19 pandemic

[vc_row][vc_column][vc_column_text]The GDHP is currently chaired by India. Mr Lav Agarwal, Joint Secretary, Ministry of Health and Family Welfare, Government of India is the GDHP Secretariat Lead.

Mr Agarwal said “Sharing digital health information is now more important than ever as individual nations and the global community respond to the challenges of the COVID-19 pandemic.”

“These White Papers will provide both participant and non-participant countries and territories with guidance on the key digital health enablers that can lead in improving the health and well-being of citizens at national and sub-national levels through the best use of evidence-based digital technologies.”

The reports provide insights, guidance and information on cutting edge digital innovation for digital health workers, governments and organisations providing digital health services, and the communities they serve across the globe.

They are a valuable source of information that provide a catalyst for positive change, with insights and international comparisons of our digital health systems with countries around the world.

One key trend of GDHP members’ digital health systems are efforts to empower citizens to have greater involvement in the management of their own healthcare. This is evidenced in Australia in statistics published by the Australian Digital Health Agency which show consumers are uploading and viewing more of their My Health Record documents.

Chief Medical Adviser at the Agency and Chair of the Evidence and Evaluation work stream for the GDHP, Clinical Professor Meredith Makeham, said the Agency had supported and led the development of the White Papers over the past year, working with more than 30 countries from around the world.

“International collaboration is critical to improving health outcomes for all,” she said.

“Many countries and territories are still at the beginning of their digital health journey, so providing insights in key areas of common interest through our GDHP participation is fundamentally beneficial and supports our goals to improve health and well-being for people.”

“Our experiences with the COVID-19 pandemic have highlighted the importance of international engagement, and the critical role that digital health technologies play in ensuring that people have access to their healthcare providers and services. Digital health has never been more important.”

“I want to highlight the role Australia has played in establishing the GDHP as the inaugural Chair of the partnership and host of its first summit in early 2018. Since then we’ve benefitted from the opportunity to share valuable insights on digital health service delivery for our citizens that have been informed by the cutting-edge work of GDHP participants around the world,” she said.

Comments from other GDHP Work Stream Chairs:

Dr Don Rucker, National Coordinator for Health IT, US Department of Health and Human Services said “Sharing information using health data standards for interoperability is necessary to advance public health reporting and research which are key parts of an evidence-driven response to pandemics. Now, more than ever, increasing collaboration and sharing best practices around the world, not just within countries and territories, is critical to advance interoperability together globally.”

Shelagh Maloney, Executive Vice President, Engagement and Marketing, Canada Health Infoway and Chair Clinical and Consumer Engagement work stream said “Over the last decade there has been a universal shift in thinking; one where there was little to no support for providing citizens with access to their information, to present day, where we are accelerating efforts to provide citizens access to information in an equitable and secure manner. As governments around the world grapple with this new reality, and citizens in many jurisdictions are asked to remain home for public health, it has never been more critical for citizens to access their health information remotely: wherever and whenever it’s needed.”

The four GDHP White Papers are:

  • Advancing Interoperability Together Globally
  • Citizen Access to Digital Health
  • Benefits Realisation: Sharing insights
  • Foundational Capabilities Framework & Assessment

[/vc_column_text][/vc_column][/vc_row]

Breakthrough 20 Minutes COVID-19 Blood Test

[vc_row][vc_column][vc_column_text]In a discovery that could advance the worldwide effort to limit the community spread of COVID-19 through robust contact tracing, researchers were able to identify recent COVID-19 cases using 25 microlitres of plasma from blood samples.

The research team, led by BioPRIA and Monash University’s Chemical Engineering Department, including researchers from the ARC Centre of Excellence in Convergent BioNano Science and Technology (CBNS), developed a simple agglutination assay – an analysis to determine the presence and amount of a substance in blood – to detect the presence of antibodies raised in response to the SARS-CoV-2 infection.

Positive COVID-19 cases caused an agglutination or a clustering of red blood cells, which was easily identifiable to the naked eye. Researchers were able to retrieve positive or negative readings in about 20 minutes.

While the current swab / PCR tests are used to identify people who are currently positive with COVID-19, the agglutination assay can determine whether someone had been recently infected once the infection is resolved – and could potentially be used to detect antibodies raised in response to vaccination to aid clinical trials.

Using a simple lab setup, this discovery could see medical practitioners across the world testing up to 200 blood samples an hour. At some hospitals with high-grade diagnostic machines, more than 700 blood samples could be tested hourly – about 16,800 each day.

Study findings could help high-risk countries with population screening, case identification, contact tracing, confirming vaccine efficacy during clinical trials, and vaccine distribution.

This world-first research was published today (Friday 17 July 2020) in the prestigious journal ACS Sensors.

A patent for the innovation has been filed and researchers are seeking commercial and government support to upscale production.

Dr Simon Corrie, Professor Gil Garnier and Professor Mark Banaszak Holl (BioPRIA and Chemical Engineering, Monash University), and Associate Professor Timothy Scott (BioPRIA, Chemical Engineering and Materials Science and Engineering, Monash University) led the study, with initial funding provided by the Chemical Engineering Department and the Monash Centre to Impact Anti-microbial Resistance.

Dr Corrie, Senior Lecturer in Chemical Engineering at Monash University and Chief Investigator in the CBNS, said the findings were exciting for governments and health care teams across the world in the race to stop the spread of COVID-19. He said this practice has the potential to become upscaled immediately for serological testing.

“Detection of antibodies in patient plasma or serum involves pipetting a mixture of reagent red blood cells (RRBCs) and antibody-containing serum/plasma onto a gel card containing separation media, incubating the card for 5-15 minutes, and using a centrifuge to separate agglutinated cells from free cells,” Dr Corrie said.

“This simple assay, based on commonly used blood typing infrastructure and already manufactured at scale, can be rolled out rapidly across Australia and beyond. This test can be used in any lab that has blood typing infrastructure, which is extremely common across the world.”

Researchers collaborated with clinicians at Monash Health to collect blood samples from people recently infected with COVID-19, as well as samples from healthy individuals sourced before the pandemic emerged.

Tests on 10 clinical blood samples involved incubating patient plasma or serum with red blood cells previously coated with short peptides representing pieces of the SARS-CoV-2 virus.

If the patient sample contained antibodies against SARS-CoV-2, these antibodies would bind to peptides and result in aggregation of the red blood cells. Researchers then used gel cards to separate aggregated cells from free cells, in order to see a line of aggregated cells indicating a positive response. In negative samples, no aggregates in the gel cards were observed.

“We found that by producing bioconjugates of anti-D-IgG and peptides from SARS-CoV-2 spike protein, and immobilising these to RRBCs, selective agglutination in gel cards was observed in the plasma collected from patients recently infected with SARS-CoV-2 in comparison to healthy plasma and negative controls,” Professor Gil Garnier, Director of BioPRIA, said.

“Importantly, negative control reactions involving either SARS-CoV-2-negative samples, or RRBCs and SARS-CoV-2-positive samples without bioconjugates, all revealed no agglutination behaviour.”

Professor Banaszak Holl, Head of Chemical Engineering at Monash University, commended the work of talented PhD students in BioPRIA and Chemical Engineering who paused their projects to help deliver this game changing COVID-19 test.

“This simple, rapid, and easily scalable approach has immediate application in SARS-CoV-2 serological testing, and is a useful platform for assay development beyond the COVID-19 pandemic. We are indebted to the work of our PhD students in bringing this to life,” Professor Banaszak Holl said.

“Funding is required in order to perform full clinical evaluation across many samples and sites. With commercial support, we can begin to manufacture and roll out this assay to the communities that need it. This can take as little as six months depending on the support we receive.”

COVID-19 has caused a worldwide viral pandemic, contributing to nearly 600,000 deaths and more than 13.8 million cases reported internationally. Australia has reported 10,810 cases and 113 deaths (figures dated 17 July 2020).[/vc_column_text][/vc_column][/vc_row]

Medibank to pay $5 million in penalties for misrepresentations to members about benefits

[vc_row][vc_column][vc_column_text]Medibank falsely advised 849 members with ahm’s “lite” or “boost” policies who had lodged claims or enquired about their coverage, that they were not covered for joint investigations or joint reconstruction procedures, when these policies in fact entitled them to coverage for these procedures. At least 1,396 enquiries or claims were incorrectly rejected.

Medibank admitted this breach occurred because it failed to include 186 joint investigation and reconstruction services in its claiming system for the ahm “lite” policy between February 2013 and July 2018, and failed to include 26 such services in its system for the “boost” policy between February 2017 and July 2018.

Despite Medibank identifying in June 2017 that some service codes had not been included, Medibank rejected 370 enquiries or claims over another 13 months, until the conduct ceased in July 2018.

The services involved included critical services, such as spinal surgery, pelvic surgery, hip surgery and knee reconstructions, as well as procedures on fibulas, elbows, heels, wrists, kneecaps and jaws.

“Medibank’s false statements to consumers were a serious breach of our consumer law. These representations were made for more than five years in many cases, and affected hundreds of customers who were denied the cover they were entitled to under their existing Medibank policies for joint procedures that they required,” ACCC Chair Rod Sims said.

“Some Medibank policy holders incurred extra out of pocket expenses for major medical procedures, some delayed having these joint procedures and managed their pain, while others ‘upgraded’ their Medibank policies at an additional cost when they didn’t have to.”

Medibank self-reported this conduct to the ACCC in August 2018 and has since notified about 130,000 current and former policy holders. It invited them to make a complaint or seek compensation. By 22 June 2020, Medibank had paid more than $775,000 in compensation to 175 affected members, including some who upgraded their policies unnecessarily based on the false information.

“Businesses who self-report breaches of the Australian Consumer Law are not exempt from ACCC enforcement action, but the penalties ordered by the court will take their cooperation into account,” Mr Sims said.

Medibank has undertaken to the ACCC that it will contact about 670 policy holders who have not already taken up Medibank’s offer for compensation and provide them with a further chance to claim. Medibank will also pay these members an additional $400 as a one-off payment.

Anyone who may be eligible will be notified by Medibank and will have six months to make a claim on the ahm website at https://members.ahm.com.au/joint-claims or can contact ahm on 134 246 or 1300 484 395.

Medibank has also undertaken to review its compliance procedures, and amend its incident management procedures.

Medibank cooperated with the ACCC’s investigation, admitted liability and made joint submissions to the Court with the ACCC.[/vc_column_text][/vc_column][/vc_row]

Australian COVID-19 Research: From vaccines to aircon filters

[vc_row][vc_column][vc_column_text]Research Australia, the national peak body for health and medical research, has released the first report in its COVID-19 series showcasing the incredible breadth of Australia’s COVID-19 research.

“Australians are rightly proud of our world-leading vaccine projects. There’s incredible work being done beyond the lab too – everything from guidelines for breastfeeding mothers to filters that have the potential to remove the coronavirus from air conditioning systems,” said Research Australia CEO, Nadia Levin.

“The true range of COVID-19 medical research is not evident to the researchers themselves, let alone governments and the general public who are relying on our medical researchers to get us through this pandemic.

“In this report we look at over 200 research projects to demonstrate the depth and breadth of COVID-19 research underway in Australia right now,” Nadia Levin said.

The volume of coronavirus medical research is testament to long-term investment in Australia’s medical research capacity, but that it had come at a cost.

“The sudden ‘downing of tools’ that must happen when researchers are called upon to pivot their research towards an urgent pandemic throws existing projects, and their funding, off course. Like other parts of the economy, health and medical research is suffering.

“Research Australia is already talking to its members about how we re-design a medical research system which can withstand these crises because there is a very real possibility COVID-19 won’t be the only pandemic we see in our lifetime,” Nadia Levin said.[/vc_column_text][/vc_column][/vc_row]

Modelling shows tracking app critical to containing COVID second wave

[vc_row][vc_column][vc_column_text]While social distancing and high rates of testing remain the best ways to limit the spread, the Sax Institute researchers behind the modelling say the smartphone app could be “insurance” against reignition of the pandemic.

The modelling, published in the peer-reviewed journal Public Health Research & Practice, uses evidence on factors such as the speed and characteristics of the virus’s spread to project likely consequences for case numbers under various scenarios.

The ‘baseline’ scenario assumes a 50% monthly decline in social distancing and a 5% monthly drop in testing intensity going forward – the authors’ estimate of what was happening in May when the paper was written. Their model finds that if 61% of the population in this scenario downloaded the COVIDSafe app onto their phones, the number of infections in a second wave would be 55% lower than if there were no app.

In contrast, the current app uptake level (27%) would have a much smaller effect, resulting in only 24% fewer cases between April and December 2020, the modelling shows.

The research team, led by the Sax Institute’s Dr Danielle Currie, Senior Simulation Modeller, and Dr Michael Frommer, Senior Adviser, say the potential alternative to an effective response centred on social distancing, testing and contact tracing assisted by the app is that “restrictions on travel and social interaction…may need to be re-introduced”.

Dr Frommer said the model projections should be a clarion call for state and federal governments to redouble their efforts in promoting the app to the public as well as ensuring that any lingering technical issues are swiftly resolved.

“Testing and social distancing will exert the biggest influence on controlling the curve of the second wave, but the tracking app can play a very important role,” he said.

“At our current uptake levels, the app will help with contact tracing, but not significantly. What our work shows is that if we can push uptake to around three-fifths of the population, then it will make a huge difference. It would halve the number of people getting COVID-19 in the event of a second wave and decrease the death rate as well.”

The study involved an extensive literature review of the epidemiology of COVID-19, case-finding practices and factors that could affect the uptake of the app, and finally the development of a robust system dynamics model based on the behaviour of the virus and its interaction with social, behavioural, and policy factors, using pandemic data from Australia and across the world. The model projects the number of people infected by the virus through to the end of the year. It can be adjusted to account for different rates of testing, intensity of social distancing and uptake of the tracking app.

The modelling study is part of a special themed issue of Public Health Research & Practice on the public health lessons we are learning from the COVID pandemic.

In a Perspective article for this issue, Professor Julie Leask and Dr Claire Hooker, both of the University of Sydney, argue that better risk communication could have reduced the controversy around school closures in Australia due to the pandemic. Events leading up to the school closures created a “near perfect storm of fright factors”, they write, escalating people’s fear while reducing their trust in those working to manage the problem. The authors offer a step-by-step guide in managing communications during health crises such as the COVID-19 pandemic.

Two other COVID-related articles in this issue of Public Health Research & Practice find:

In an editorial for this issue, the journal’s Editor-in-Chief Professor Don Nutbeam, Principal Senior Adviser at the Sax Institute and Professor of Public Health at the University of Sydney, writes that maintaining the fragile consensus between governments, their scientific advisers and their citizens is critical to the successful control of the virus.

“The consensus will be sustained by mutual trust built on effective communication – between scientists and policy makers, and between governments and their populations.”[/vc_column_text][/vc_column][/vc_row]

PRIVATE HEALTH INSURERS BACKFLIP ON COVID-19 REFUND

[vc_row][vc_column][vc_column_text]Following the announcement of elective surgery bans earlier this year, the insurers made a commitment to ensure they weren’t unduly profiting from the crisis, with PHA CEO Rachel David quoted in the Australian Financial Review on April 8 as saying “if members are getting less for their money – we will address it”.

Fast forward two months, and NIB CEO Mark Fitzgibbon has said that any premium relief looks unlikely, due to the crisis peaking earlier than expected.

“Reduced hospital and ancillary activity did occur in April and into May but quickly recovered and in recent weeks we’ve seen claiming return to normal levels,” said Mr Fitzgibbon this week.

Health workers and industry players across the country, from frontline workers, to researchers and manufacturers have pulled out all the stops in recent months to help fight COVID-19.

“The entire healthcare system has pulled together in an unprecedented effort to support the Australian community through the pandemic, under the strain of enormous cost pressures,” said Ian Burgess, Medical Technology of Australia (MTAA) CEO.

“A significant number of MedTech companies have suffered reductions in revenue of up to 90% as a result of the elective surgery ban.

“This is further compounded by an increase of freight costs of up to 500% and a fall in the Aussie dollar.

“It’s time for the private health insurers to do their bit, rather than just pocketing profits off the back of a global health and economic crisis,” Mr Burgess said.[/vc_column_text][/vc_column][/vc_row]

Better connected healthcare system already showing improved secure transfer of patient information

[vc_row][vc_column][vc_column_text]Out of date contact details that healthcare providers have about healthcare services and other practitioners can mean that patients’ medical documents and information is not able to be sent from one healthcare provider to another. In a world where consumers can no longer be a conduit for delivering a referral letter or test result to another provider, and where our postal services are over capacity, an up to date electronic registry is more important than ever.

The Australian Digital Health Agency has built a Service Registration Assistant (SRA) to solve this problem. The SRA keeps healthcare service and practitioner information up to date with changes to contact details available immediately to authorised users.

Healthcare organisations can update their details in the SRA once, and this will automatically send these new details to all organisations they have authorised to receive their information. This might include hospitals, pathology and radiology services, public service directories, secure messaging providers and more. The SRA avoids the need for an organisation to update their information in multiple places and eliminates the need for hundreds of other directories around the country to manually keep their directories up to date.

Dr Steve Hambleton, a General Practitioner and Agency Clinical Reference Lead,  noted that “not only will this innovation bring about efficiencies for practice support staff who will only have to update changes in practice information once, it will increase confidence at the point of care that all of the incoming information about our patients will be there, and that our outgoing address book is complete and up to date”.

Initial results from a trial of the SRA in Northern NSW has shown significant improvements in communications between healthcare providers. To date, of 187 practitioners who participated in the trial and shared their details with the Northern NSW Local Health District (NNSWLHD), 186 had to change or update their details during the trial period.

For the NNSWLHD, having the most up-to-date contact information is essential to ensuring hospital discharge summaries get to the right person as quickly as possible.

Discharge summaries can include information about a patient’s assessment, treatment plan and progress notes from their hospital clinician, and a digital copy is sent via a secure service to the patient’s nominated GP. This helps the GP to continue post hospital care through follow up appointments.

Interim CEO of the Australian Digital Health Agency, Bettina McMahon said maintaining accurate provider address details was a longstanding challenge across the Australian healthcare sector.

“What is great to see is that the necessary, reliable and timely sharing of patients’ healthcare information between their healthcare providers is being improved by this latest feature of Australia’s digital health system,” she said.

“Healthcare providers all over Australia are enthusiastically using digital health so we want to make things as easy and efficient for them as possible. This tool will bring the benefits of digital health to more Australians.”

The trial is a partnership between the Agency, the NNSWLHD and the North Coast Primary Health Network (NCPHN).

CEO of NCPHN Julie Sturgess said “The opportunity to trial the SRA means local healthcare providers are able to be at the forefront of innovation in digital health to drive better patient outcomes. The results from the trial are really positive and we are keen to continue to work with the Agency on the next phase of the trial.”

Chief Executive of the NNSWLHD Wayne Jones said “We’re always looking at ways to improve the experience of patients in our care, and this system will help support the safe transfer of care of our patients from hospital to their GP.”

Australian Association of Practice Managers’ CEO Nicholas Voudouris said “Practice managers play a key role in ensuring a patient’s healthcare providers – wherever they work and whoever they work for – have accurate and timely clinical information. That is why we welcomed this trial of new technology.”

After the completion of the trial, the SRA will be expanded to provide a better-connected healthcare system, improve the transfer of care between healthcare providers and give healthcare providers more timely and complete information to support the care of their patients.[/vc_column_text][/vc_column][/vc_row]

Private health is still not worth it for many Australians

[vc_row][vc_column][vc_column_text]As Federal and State Governments open up elective surgeries, consumer advocate CHOICE is warning Australians they may still not get value out of their private health insurance.

“For many Australians it will be a relief to have their elective surgeries back on track,” says Dean Price, Health Campaigner at CHOICE.

“But private health insurers are still set to reap huge savings from the elective surgeries still being deferred and the extras many are unable to claim. These savings shouldn’t be going to private health profits, they should be swiftly back in the pockets of Australians as we deal with the economic and social cost of COVID-19.”

CHOICE advises (depending on personal circumstances) that Australians should consider:

1)  Dropping extras cover

“This year you’ll be unable to claim for many of your extras. Consider whether you’ll get value for your extras this year,” says Price.

2)  Asking for hardship

“If COVID-19 has put you and your loved ones in financial hardship, you can ask your private health insurer to waive premiums or suspend your policy,” says Price.

3)  Dropping or downgrading your hospital cover

“You don’t need private health cover to be treated for COVID-19 and the usual benefits of private health might not even be available to you right now, so you may consider dropping it completely for more pressing financial pressures you have,” says Price.

CHOICE is calling for a review of the private health system.

“This pandemic has highlighted many of the problems and inequities in the private health insurance and hospital systems. Surgeries have been cancelled and other services limited, health funds are charging us for services we can’t use. It will be some time until our health

system is back to normal, but the health funds continue to charge many of us as if everything is normal,” says Price.

“People need premium relief. With 80% of people with private health insurance rating it as their number one cost of living concern before this global health and economic crisis, people will be again questioning the value of this product. People will continue to drop out of the health insurance market unless the government reviews the system and then takes strong action to ensure fair healthcare,” says Price.

“The problems of cost and value are not new to this pandemic, even if they are different. The Australian Government needs to commission a thorough, independent and public review of the private health insurance system,” says Price.

Australians can join the campaign for a better private health insurance and a review at: https://action.choice.com.au/page/59237/petition/1[/vc_column_text][/vc_column][/vc_row]

MEDTRONIC SHARES VENTILATION DESIGN SPECIFICATIONS TO ACCELERATE EFFORTS TO INCREASE GLOBAL VENTILATOR PRODUCTION

[vc_row][vc_column][vc_column_text]Introduced in 2010, the PB 560 is sold in 35 countries around the world. This ventilator’s ability to be used in a range of care settings, as well as its technology and design, make it a solid ventilation solution for manufacturers, inventors, start-ups, and academic institutions seeking to quickly ramp up ventilator design and production. PB 560 product and service manuals, design requirement documents, manufacturing documents, and schematics are now available at Medtronic.com/openventilator. The PB 560 design specifications are available today, software code and other information will follow shortly.

The PB 560 ventilator is a compact, lightweight, and portable ventilator that provides airway support for both adults and children. It can be used in clinical settings and at home and provides mobile respiratory support.

“Medtronic recognizes the acute need for ventilators as life-saving devices in the management of COVID-19 infections. We know this global crisis needs a global response. Over the past few weeks, we have ramped up production of our Puritan Bennett™ 980 ventilators. But we also know we can do more, and we are,” said Bob White, executive vice president and president of the Minimally Invasive Therapies Group at Medtronic. “By openly sharing the PB 560 design information, we hope to increase global production of ventilator solutions for the fight against COVID-19.”

Ventilators play a critical role in the management of patients with severe respiratory illness, such as COVID-19, who require assistance because they cannot breathe effectively. By placing a patient on a ventilator, the patient’s lungs are permitted to rest and recover while the ventilator performs the functions of supplying oxygen and simulating the actions of breathing. Without ventilation support, some patients with severe respiratory disease might not survive.[/vc_column_text][/vc_column][/vc_row]